Advertisement

Cardiovascular Drugs and Therapy

, Volume 10, Issue 6, pp 735–742 | Cite as

Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure

  • Udho Thadani
Coronary Artery Disease

Summary

Vascular tolerance develops rapidly in isolated vascular strips exposed to millimolar concentrations of nitroglycerin. Several mechanisms, including depletion of sulfhydryl groups, reduced biotransformation of nitrates to NO or nitrosothiols, oxygen free radical injury, and downregulation of a membrane-bound enzyme or a nitrate receptor, have been proposed, but the exact mechanism responsible for in-vitro tolerance remains unknown. In-vivo tolerance of the beneficial effects of nitrates on hemodynamics, myocardial ischemia, and exercise performance develops rapidly. It has been suggested, but remains to be proven, that development of venous tolerance and not arterial tolerance is responsible for the attenuation of nitrate effects during long-term nitrate therapy. Several mechanisms, including neurohormonal activation, depletion of sulfhydryl groups, and the shift of fluid from the extravascular to intravascular compartment have been implicated. However, the use of agents to counteract these mechanisms (ACE inhibitors, sulfhydryl donors, diuretics) has produced conflicting results. Thus, at present the mechanism responsible for in vivo tolerance to nitrates remains unknown. Both in vitro and in vivo vascular tolerance to nitrates can be prevented or minimized by providing nitrate-free or low-nitrate intervals. However, during nitrate-free periods, rebound phenomena (rest angina in patients with ischemic heart disease or a deterioration in exercise performance prior to the renewal of the morning dose in patients with stable angina) remain a clinicla concer. When treating patients with stable angina pectoris, it must be recognized that none of the nitrate preparations or formulations can provide round-the-clock antianginal or antiischemic prophylaxis. In these patients, beneficial antianginal and anti-ischemic effects of nitrates for 10–14 hours during the day-time can be maintained by using formulations and dosing regimens that avoid or minimize the development of tolerance (standard formulation of isosorbide-5-mononitrate, 20 mg in the morning and 7 hours later; slow-release formulation of isosorbide-5-mononitrate, 120–240 mg once a day; or nitroglycerin patch delivering 0.6 nitroglycerin per hour for 10–12 hours each day). Only the patch on an off treatment is associated with nitrate rebound. Although intermittent nitrate therapy is not associated with the development of tolerance, this strategy cannot be recommended for treating unstable angina because rebound angina during nitrate-free periods complicates clinical decision making. In the acute phase of unstable angina, continuous treatment with intravenous nitroglycerin is recommended because it permits rapid up- or down-titration. Tolerance towards antianginal and antiischemic effects does develop in a substantial number of patients within 24 hours, but this can be overridden by dose escalation and restoration of the therapeutic effectiveness of nitroglycerin. Tolerance towards the beneficial effects of nitrates on hemodynamics and on exercise performance also develops rapidly during continuous or long-term nitrate therapy, and for these reasons nitrates are not used as first-line therapy to treat chronic heart failure. In combination with hydralazine, high-dose isosorbide dinitrate (30–40 mg four times a day) improves survival, but this combination therapy is inferior to ACE inhibitors.

Key Words

nitrate tolerance rebound stable angina pectoris unstable angina heart failure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thadani, U, Whitsett, T, Hamilton, SF. Nitrate therapy for myocardial ischemic syndromes: Current perspectives including tolerance. Curr Prob Cardiol 1988;13:725–784.Google Scholar
  2. 2.
    Schwartz, AM. The cause, relief and prevention of headaches arising from contact with dynamite. N Engl J Med 1946;235:651.Google Scholar
  3. 3.
    Stewart, DD. Tolerance to nitroglycerin. JAMA 1910;54:783.Google Scholar
  4. 4.
    Bogaert, MA, DeSchaepdryver, AF. Tolerance towards glyceryl trinitrate (Trinitrin) in dogs. Arch Int Pharmacodyn Ther 1968;171:221–224.Google Scholar
  5. 5.
    Needleman, P. Tolerance to the vascular effects of glyceryl trinitrin. J Pharmacol Exp Ther 1970;171:98–102.Google Scholar
  6. 6.
    Crandall, LA, Leake, CD, Loevenhart, AS, et al. Acquired tolerance to and cross tolerance between the nitrates and nitric oxide esters and sodium nitrate in man. J Pharmacol Exp Ther 1981;41:103–119.Google Scholar
  7. 7.
    Schelling, JL, Lasagne, L. A study of cross tolerance to circulatory effects of organintrates. Clin Pharmacol Ther 1967;8:256–260.Google Scholar
  8. 8.
    Thadani, U, Manyari, D, Parker, JO, et al. Tolerance to the circulatory effects of oral isosorbide dinitrate: Rate of development and cross tolerance to glyceryl trinitrate. Circulation 1980;61:526–535.Google Scholar
  9. 9.
    Abrams, J. Nitrate tolerance and dependence. Am Heart J 1980;99:113–123.Google Scholar
  10. 10.
    Abrams, J. Nitroglycerin and long-acting nitrates in clinical practice. Am J Med 1983;74:85–94.Google Scholar
  11. 11.
    Thadani, U, Fung, HL, Darke, AC, et al. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982;49:411–419.Google Scholar
  12. 12.
    Rudolph, W, Blasini, R, Reinger, G, et al. Tolerance development during dinitrate treatment: Can it be circumvented? Z Kardiol 1983;72(Suppl 3):195–198.Google Scholar
  13. 13.
    Steering Committee; Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous 24-hour application of trandermal nitroglycerin. Am J Cardiol 1991;63:1263–1273.Google Scholar
  14. 14.
    Thadani, U, Lipicky, RJ. Short and long-acting nitrates for stable angina pectoris. Cardiovasc Drugs Ther, 1994;8:611–623.Google Scholar
  15. 15.
    Thadani, U, Lipicky, RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994;8:625–633.Google Scholar
  16. 16.
    Thadani, U, Sharma, M, Thompson, D, et al. Intravenous nitroglycerin and tolerance in unstable angina (abstr). Circulation 1987;76:(Suppl IV):IV128.Google Scholar
  17. 17.
    Curfman, GD, Heinsimer, JA, Lozner, EC, et al. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: A prospective, randomized trial. Circulation 1983;67:276–283.Google Scholar
  18. 18.
    Thadani, U, Opie, LH. Nitrates for unstable angina. Cardiovasc Drugs Ther 1994;8:719–726.Google Scholar
  19. 19.
    Packer, M, Lee, WH, Kessler, PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799–804.Google Scholar
  20. 20.
    Dupuis, J, Lalonde, G, Lemieux, R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcsteine. J Am Coll Cardiol 1990;16:923–931.Google Scholar
  21. 21.
    Elkayam, U. Tolerance to organic nitrates: Evidence, mechanisms, clinical evidence and strategies for prevention. Ann Intern Med 1991;114:667–677.Google Scholar
  22. 22.
    Morton, WE. Occupational habituation to aliphatic nitrates and the withdrawal hazards of coronary disease and hypertension. J Occup Med 1977;19:197–199.Google Scholar
  23. 23.
    Klock, JC. Nonocclusive coronary disease after chronic exposure to nitrates for physiologic nitrate dependence. Am Heart J 1975;80:510.Google Scholar
  24. 24.
    Demots, H, Glasser, SP, and the Transderm Nitro Study Group. Intermittent nitroglycerin therapy in treatment of stable angina. J Am Coll Cardiol 1989;13:786–793.Google Scholar
  25. 25.
    Ahlner, J, Andersson, RCG, Torfgard, K, Axelsson, KL. Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol Rev 1991;43:351–423.Google Scholar
  26. 26.
    Fung, H-L, Bauer, JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489–499.Google Scholar
  27. 27.
    Kowaluk, E, Hough, K, Fung, H-L. Effect of intermittent exposure and drug-free intervals on the in vitro vascular tolerance to nitroglycerin. Life Sci 1989;44:1157–1163.Google Scholar
  28. 28.
    Needleman, P, Johnson, EMJr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973; 184:709–715.Google Scholar
  29. 29.
    Fung, H-L, Chong, S, Kowaluk, E. Mechanisms of nitrate action and vascular tolerance. Eur Heart J 1989;10 (Suppl. A):2–6.Google Scholar
  30. 30.
    Münzel, T, Sayegh, H, Freeman, BA, et al. Evidence for enhanced vascular super oxide anion production in nitrate tolerance: A novel mechanism of tolerance and cross tolerance. J Clin Invest 1995;95:187–194.Google Scholar
  31. 31.
    Lam, JY, Chesebro, JH, Fuster, V. Platelets, vasoconstriction and nitroglycerin during arterial wall injury. A new antithrombotic role of an old drug. Circulation 1988;78:712–716.Google Scholar
  32. 32.
    Folts, JD, Stamler, J, Loscalzo, J. Intravenous nitroglyerin infusion inhibits cyclic flow response caused by periodic platelet thrombus formation in stenosed coronary arteries. Circulation 1991;83:2122–2127.Google Scholar
  33. 33.
    Diodati, Theroux, P, Latour, J-G, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation: Unstable angina and acute myocardial infarction. Am J Cardiol 1990;66:683–688.Google Scholar
  34. 34.
    Zelis, R, Mason, DT. Isosorbide dinitrate: Effects on the vasodilator response to nitroglycerin. JAMA 1975;234:166–170.Google Scholar
  35. 35.
    Manyari, DE, Smith, ER, Spragg, J. Isosorbide dinitrate and glyceryl trinitrate: Demonstration of cross tolerance in the capacitance vessels. Am J Cardiol 1985;55:927–931.Google Scholar
  36. 36.
    Ghio, S, Deservi, S, Perotti, S, et al. Differential susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans: Effects of N-acetylcysteine administration. Circulation 1992;86:798–802.Google Scholar
  37. 37.
    Makhoul, N, Dakak, N, Flugelman, MY, et al. Nitrate tolerance in heart failure-differential venous, pulmonary and systemic arterial effects. Am J Cardiol 1990;65:J28-J32.Google Scholar
  38. 38.
    Leier, CV, Huss, P, Magorien, RD, Unverferth, DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67:817–822.Google Scholar
  39. 39.
    Steward, DJ, Elsner, D, Sommer, O, Holtz, J, Bassange, E. Altered spectrum of nitroglycerin action in long-term treatment: Nitroglycerin specific venous tolerance with maintenance of arterial vasodepressor potency. Circulation 1986;74:573–582.Google Scholar
  40. 40.
    Jeserich, M, Münzel, T, Pape, L, et al. Absence of vascular tolerance in conductance vessels after 48 hours intravenous nitroglycerin in patients with coronary artery disease. Am J Coll Cardiol 1995;26:50–56.Google Scholar
  41. 41.
    Münzel, T, Heitzer, T, Kurzs, et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol 1996;27:297–303.Google Scholar
  42. 42.
    Kai, H, Yamamoto, H, Nomo, H, et al. Effects of continuous intravenous infusion of isosorbide dinitrate on development of tolerance to vasodilating action in human epicardial coronary arteries. Am Heart J 1994;128:230–236.Google Scholar
  43. 43.
    Zimrin, D, Reichek, M, Bogin, KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376–1384.Google Scholar
  44. 44.
    Parker, JO, Fung, HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471–476.Google Scholar
  45. 45.
    Scardi, S, Camareni, F, Pandullo, G, et al. Efficacy of continuous and intermittent transdermal treatment with nitroglycerin in effort induced angina pectoris: A multicenter study. Int J Cardiol 1991;32:241–248.Google Scholar
  46. 46.
    Bassan, MM. The day long pattern of antianginal effect of long term three times daily administration of isosorbide dinitrate. J Am Coll Cardiol 1990;16:936–940.Google Scholar
  47. 47.
    Thadani, U, Fung, HL, Darke, AC, et al. Oral isosorbide dinitrate in the treatment of angina pectoris: Dose-response relationship and duration of action during acute therapy. Circulation 1980;62:491–502.Google Scholar
  48. 48.
    Parker, JO, Farrell, B, Lahey, KA, et al. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987;316:1440–1444.Google Scholar
  49. 49.
    Tauchert, M, Jansen, W, Osterspey, A, et al. Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 1983;73(Suppl 3):218–228.Google Scholar
  50. 50.
    Parker, JO, Farrell, LB, Lahey, KA, et al. Intrate tolerance: The lack of effect of N-acetylcysteine. Circulation 1987;76:572–576.Google Scholar
  51. 51.
    Dakak, N, Makhoul, N, Flugelman, MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608–612.Google Scholar
  52. 52.
    Parker, JO, Farrell, B, Fenton, T, et al. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992;20:616–620.Google Scholar
  53. 53.
    Seth, P, Fung, HL. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol 1993;46:1481–1486.Google Scholar
  54. 54.
    Thadani, U, Opie, LH. Nitrates. In: Opie, LH, ed. Drugs for the Heart, 4th ed. Philadelphia: WB Saunders, 1995:31–48.Google Scholar
  55. 55.
    Thadani, U, Maranda, C, Amsterdam, E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994;120:353–359.Google Scholar
  56. 56.
    Parker, JO and the Isosorbide-5-mononitrate Study Group. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993;72:871–876.Google Scholar
  57. 57.
    Chrysant, SG, Glasser, SP, Bittar, N, et al. Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249–1256.Google Scholar
  58. 58.
    Thadani, U, Bittar, N. Effects of 8:00 am and 2:00 pm doses of isosorbide-5-mononitrate during twice daily therapy in stable angina pectoris. Am J Cardiol 1992;70:286–292.Google Scholar
  59. 59.
    Davis, MJ, Thomas, AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363–373.Google Scholar
  60. 60.
    Fuster, V, Chesebro, JH. Mechanisms of unstable angina. N Engl J Med 1986;315:1023–1025.Google Scholar
  61. 61.
    Cohn, JN, Archibald, D, Ziesche, S, et al. Effect of vasodilator therapy on mortality in chronic heart failure. Results of a Veterans Administration Cooperative Study (V-Heft) N Eng J Med 1986;314:1547–1552.Google Scholar
  62. 62.
    Cohn, JN, Johnson, G, Ziesche, S, et al. A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.Google Scholar
  63. 63.
    Bauer, JA, Fung, H-L. Concurrent administration of hydralazine prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35–39.Google Scholar
  64. 64.
    Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995.Google Scholar
  65. 65.
    Holdright, DR, Katz, RJ, Wright, CA, et al. Lack of rebound during intermittent transdermal treatment with glyceryl trinitrate in patients with stable angina on background β blocker. Br Heart J 1993;69:223–227.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Udho Thadani
    • 1
    • 2
  1. 1.Health Sciences CenterUniversity of OklahomaOklahoma CityUSA
  2. 2.VA Medical CenterOklahoma CityUSA

Personalised recommendations